|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2023―Jun―03 |
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial |
Noémie Mercier, Drifa Belhadi, Aline DeChanet, Christelle Delmas, Juliette Saillard, Marina Dumousseaux, et al. (+18) Soizic Le Mestre, Claire Fougerou-Leurent, Assia Ferrane, Charles Burdet, Hélène Espérou, Florence Ader, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Claire Andrejak, José Artur Paiva, Evelina Tacconelli, Thérèse Staub, Richard Greil, Dominique Costagliola, France Mentre, Yazdan Yazdanpanah, Alpha Diallo |
2 |
[GO] |
2023―May―03 |
The influence of
SARS-CoV
-2 infection on expression of drug-metabolizing enzymes and transporters in a
hACE2
murine model |
Kiran Deshpande, Keith R. Lange, William B. Stone, Christine Yohn, Naomi Schlesinger, Leonid Kagan, et al. (+3) Albert J. Auguste, Bonnie L. Firestein, Luigi Brunetti |
3 |
[GO] |
2023―Apr―11 |
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19 |
Rodolfo Pedro Rothlin, Facundo Germán Pelorosso, Mariano Duarte, Liliana Nicolosi, Fernandez Criado Ignacio, María Victoria Salgado, Héctor Vetulli |
4 |
[GO] |
2022―Dec―20 |
Phase 1 study of safety, pharmacokinetics, and antiviral activity of
SARS-CoV
-2 neutralizing monoclonal antibody
ABBV-47D11
in patients with
COVID
-19 |
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, et al. (+9) John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami |
5 |
[GO] |
2022―Sep―01 |
Toward a big picture of COVID-19 |
Felix Tretter, Janet J. McIntyre-Mills, Gary R. Smith |
6 |
[GO] |
2022―Jul―15 |
A practical treatment for
COVID
-19 and the next pandemic |
Jahar Bhattacharya, Robert Booy, Arturo Casadevall, Charles Dela Cruz, David S. Fedson, Joe G. N. Garcia, et al. (+11) Gary Grohmann, Ivan F. N. Hung, Jeffrey R. Jacobson, Lance C. Jennings, Lester Kobzik, Aleksandra Leligdowicz, James K. Liao, Jennifer H. Martin, Daniel M. Musher, Charles N. Serhan, Masato Tashiro |
7 |
[GO] |
2022―Apr―09 |
Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19 |
Henrik Berg Rasmussen, Ragnar Thomsen, Peter Riis Hansen |
8 |
[GO] |
2022―Feb―02 |
Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment |
Richard J. Head, Eugenie R. Lumbers, Bevyn Jarrott, Felix Tretter, Gary Smith, Kirsty G. Pringle, et al. (+2) Saiful Islam, Jennifer H. Martin |
9 |
[GO] |
2022―Feb―02 |
The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment |
Eugenie R. Lumbers, Richard Head, Gary R. Smith, Sarah J. Delforce, Bevyn Jarrott, Jennifer Martin, Kirsty G. Pringle |
10 |
[GO] |
2022―Feb―02 |
Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology |
Jennifer H. Martin, Richard J. Head |
11 |
[GO] |
2021―Dec―30 |
Molnupiravir: A new candidate for COVID-19 treatment |
Fariba Pourkarim, Samira Pourtaghi-Anvarian, Haleh Rezaee |
12 |
[GO] |
2021―Oct―28 |
Did our pharmacological strategy for COVID-19 fail? |
Jennifer H. Martin, Michelle Baddeley, Richard Head |
13 |
[GO] |
2021―Oct―28 |
Statin withdrawal and treating COVID-19 patients |
David S. Fedson |
14 |
[GO] |
2021―Oct―10 |
Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic |
Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo |
15 |
[GO] |
2021―Jun―15 |
Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data |
Harri Hemilä, Elizabeth Chalker |
16 |
[GO] |
2021―Jun―15 |
p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication:
In silico
predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein |
Athanasios Panagiotopoulos, Melpomeni Tseliou, Ioannis Karakasiliotis, Danai-Maria Kotzampasi, Vangelis Daskalakis, Nikolaos Kesesidis, et al. (+6) George Notas, Christos Lionis, Marilena Kampa, Stergios Pirintsos, George Sourvinos, Elias Castanas |
17 |
[GO] |
2021―Mar―12 |
Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19 |
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, et al. (+2) Alexander Supady, Achim Lother |
18 |
[GO] |
2021―Jan―15 |
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview |
Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi-Anvarian, Taher Entezari-Maleki, Touraj Asvadi-Kermani, Masoud Nouri-Vaskeh |
19 |
[GO] |
2020―Dec―31 |
Therapeutic approaches against coronaviruses acute respiratory syndrome |
Camilla Servidio, Francesco Stellacci |
20 |
[GO] |
2020―Dec―25 |
Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract |
Ismail A. El-Shimy, Mahmoud M. A. Mohamed, Syed Shahzad Hasan, Muhammad A. Hadi |
21 |
[GO] |
2020―Oct―30 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase |
Jingyue Ju, Xiaoxu Li, Shiv Kumar, Steffen Jockusch, Minchen Chien, Chuanjuan Tao, et al. (+4) Irina Morozova, Sergey Kalachikov, Robert N. Kirchdoerfer, James J. Russo |
22 |
[GO] |
2020―Oct―21 |
A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? |
Amanj Kurdi, Nouf Abutheraa, Lina Akil, Brian Godman |
23 |
[GO] |
2020―Sep―28 |
Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19 |
Paula M. Heister, Robin N. Poston |
24 |
[GO] |
2020―Jul―27 |
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients |
Bruce M. Hendry, Nina Stafford, Ahran D. Arnold, Arvind Sangwaiya, Vijay Manglam, Stuart D. Rosen, Jayantha Arnold |
25 |
[GO] |
2020―Jul―13 |
The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19 |
Cássia L. Braga, Rodrigo P. Silva-Aguiar, Denise Battaglini, Diogo B. Peruchetti, Chiara Robba, Paolo Pelosi, et al. (+3) Patricia R. M. Rocco, Celso Caruso-Neves, Pedro L. Silva |
26 |
[GO] |
2020―Jun―24 |
Buying time: Drug repurposing to treat the host in COVID-19H |
Jennifer H. Martin, Julian Clark, Richard Head |